2022-11-08T13:12:17-06:00 2021-12-31 271728945 PKF O'CONNOR DAVIES LLP 3001 SUMMER STREET 5TH FLOOR EAST STAMFORD CT 06905 990 2021-01-01 061504413 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULT 2032290464 383 MAIN AVE 5TH FL NORWALK CT 06851 ROBERT MIANI TREASURER/CFO 2032290464 2022-11-08 1 ROBERT MIANI XXX-XX-XXXX GARRETT M HIGGINS P00543209 2033232400 2022-11-08 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z MICHAEL ANDREINI 383 MAIN AVE 5TH FL NORWALK CT 06851 137690657 0 X WWW.THEMMRF.ORG X 1998 CT SEE SCHEDULE O 18 17 74 343 0 0 25012712 37089868 2546093 2348850 -1530381 2872478 758795 0 26787219 42311196 1830765 6629658 0 0 8945794 11130870 0 0 3821015 17769173 19886535 28545732 37647063 -1758513 4664133 73276923 85401847 20009693 28167047 53267230 57234800 X SEE SCHEDULE O 0 0 6057158 6057158 THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SUPPORTS INVESTIGATORS AND SCIENTIFIC PROJECTS THROUGH A NUMBER OF RESEARCH GRANTS. THE GOAL OF THIS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC APPROACHES FOR MYELOMA THROUGH OUR UNIQUE END-TO-END MODEL THAT SUPPORTS EFFORTS IN BASIC SCIENCE OR TRANSLATION RESEARCH.IN 2021, THE MMRF CONTINUED TO BUILD OUT THE MMRF IMMUNE ATLAS INITIATIVE ("THE ATLAS"), AN IMMUNE PROFILING AND ANALYTICS PLATFORM USING DATA AND SAMPLES FROM THE COMMPASS STUDY TO GENERATE DATA ON THE ROLE OF PATIENT IMMUNITY IN MYELOMA DISEASE BIOLOGY AND RESPONSE TO THERAPY, AND TO SUPPORT AND SPEED EFFORTS TO MAKE IMMUNOTHERAPY MORE PRECISE TO LEVERAGE IMMUNOTHERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA. THE IMMUNE ATLAS WILL DESCRIBE THE IMMUNE LANDSCAPE IN MYELOMA AND HOW IT CHANGES THROUGHOUT THE COURSE OF THE DISEASEAND TREATMENT. THIS EFFORT IS A CRITICAL FIRST STEP TO ESTABLISH STANDARDS AND ALIGNMENT ON HOW IMMUNE DATA IS PRODUCED, PRIORITIZED, AGGREGATED, AND SHARED. AT SCALE, IT HAS THE POTENTIAL TO IDENTIFY NEW IMMUNOLOGIC FACTORS PREDICTIVE OF PATIENT RESPONSE OR RELAPSE TO THERAPY, TO IDENTIFY NEW IMMUNE TARGETS FOR DRUG DEVELOPMENT AND, EVENTUALLY, ENABLE CLINICIANS TO CUSTOMIZE TREATMENTS AND THERAPIES BASED ON AN INDIVIDUAL'S IMMUNE SYSTEM.IN JULY 2020, THE MMRF LAUNCHED THE MMRF CURECLOUD ("CURECLOUD"), A DIRECT-TO-PATIENT REGISTRY THAT OFFERS PATIENTS THE FIRST AT-HOME GENOMIC TESTING PROGRAM AND THE RETURN OF A CLINICAL GRADE REPORT THAT CAN BE USED TO IDENTIFY TREATMENTS AND TRIALS THAT MAY BE RIGHT FOR THEIR CARE. THE AGGREGATED CURECLOUD DATA WILL ALSO BE USED TO DRIVE NEW SCIENTIFIC DISCOVERIES FOR RESEARCHERS THAT WILL GUIDE THE DEVELOPMENT OF NEW TREATMENTS AND CARE PATHWAYS TO IMPROVE OUTCOMES FOR ALL PATIENTS. THE MMRF PLANS TO RECRUIT 5,000 PATIENTS WITH SMOLDERING AND ACTIVE MULTIPLE MYELOMA, WITH 890 PATIENTS ENROLLED BY THE END OF 2021. 4175880 572500 2348850 A KEY COMPONENT OF OUR RESEARCH PROGRAMS HAS BEEN OUR ABILITY TO PARTNER WITH OUR NETWORK OF LEADING ACADEMIC MYELOMA CENTERS THROUGH THE MMRC (MULTIPLE MYELOMA RESEARCH CONSORTIUM). THE MMRC IS A NETWORK OF 21 LEADING CANCER CENTERS AND ADDRESSES THREE CRITICAL AREAS OF UNMET NEED: HIGH-RISK SMOLDERING MYELOMA, HIGH-RISK UPFRONT TREATMENT FOR SYMPTOMATIC MULTIPLE MYELOMA, AND RELAPSED/REFRACTORY TREATMENT AFTER ANTI-CD38 AND BCMA-DIRECTED THERAPIES. 3706744 0 0 THE MMRF-SPONSORED COMMPASS STUDY COMMENCED IN 2011, AND 1,150 NEWLY DIAGNOSED, UNTREATED PATIENTS WITH ACTIVE MULTIPLE MYELOMA FROM 76 SITES (I.E., HOSPITALS, ACADEMIC MEDICAL CENTERS, AND OTHER COMMUNITY HEALTH CENTERS) IN FOUR COUNTRIES HAD BEEN ENROLLED BY 2015, AT WHICH TIME THE STUDY WAS CLOSED TO NEW PATIENT RECRUITMENT. PATIENTS ARE FOLLOWED FOR EIGHT YEARS THROUGH 2023. NO EXPERIMENTAL TREATMENTS ARE TESTED IN THE STUDY; RATHER, PATIENTS ARE PRESCRIBED STANDARD OF CARE AGENTS BY THEIR PHYSICIAN, AND BLOOD AND BONE MARROW SAMPLES ARE TAKEN FROM THE PATIENTS WHEN THERE IS A CHANGE IN THEIR DISEASE STATUS. THE TISSUE SAMPLES COLLECTED ARE PLACED IN A BIOBANK. AN UNRELATED, THIRD PARTY, NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE THEN PERFORMS LABORATORY TESTS ON A PORTION OF EACH OF THE SAMPLES RESULTING IN GENOMIC DATA ABOUT EACH PATIENT. THE MMRF LAUNCHED A SIMILAR SAMPLE/DATA SHARING COLLABORATION WITH EASTERN COOPERATIVE ONCOLOGY GROUP (THE "ECOG"). THE FINDINGS CANNOT BE PATENTED, AND ALL THE DATA ARE PLACED ON A PUBLIC PORTAL (THE MMRF RESEARCHER GATEWAY). THE RESULTING DATA REPOSITORY IS THE MOST COMPREHENSIVE CATALOG OF MULTIPLE MYELOMA AND CONTAINS THE GREATEST AMOUNT OF WHOLE GENOME SEQUENCING DATA OF ANY CANCER, ACCESSIBLE TO ANY RESEARCHER IN THE WORLD. IT WILL PROVIDE FOR MORE INFORMATION THAN IS AVAILABLE FROM CURRENT CANCER TISSUE BANKS THAT TYPICALLY INCLUDE ONLY ONE SAMPLE PER PATIENT. 18592347 0 0 IN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH IDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. AS A PATIENT-FOUNDED ORGANIZATION, THE MMRF STANDS TOGETHER WITH THOSE WHO ARE BATTLING MULTIPLE MYELOMA - PATIENTS, FAMILIES, PHYSICIANS, RESEARCHERS, AND INVESTORS. AT THE SAME TIME, THE MMRF STANDS APART WITH ITS INNOVATIVE APPROACH. THE MMRF GENERATES, INTERPRETS, AND ACTIVATES THE LARGEST COLLECTION OF HIGH-QUALITY DATA AND PLACES IT IN THE PUBLIC DOMAIN. THE MMRF ORCHESTRATES THE PEOPLE, PROGRAMS, AND TECHNOLOGIES NECESSARY TO SPEED THE DISCOVERY OF A CURE. 18592347 0 0 32532129 1 1 0 0 0 0 0 0 0 0 1 0 1 0 1 1 0 1 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 44 0 74 1 0 0 0 0 0 0 0 0 0 0 0 0 X 18 17 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA IL KS KY MD MA MI MN MS NH NJ NY NC OR PA RI SC TN UT VA WI WV X X X ROBERT MIANI 2036520207 383 MAIN AVE 5TH FLOOR NORWALK CT 06851 KATHY GIUSTI FOUNDER & CHIEF MISSION OFFICER 45.00 X 612455 0 12770 MICHAEL MORTIMER CHAIRMAN 2.00 X X 0 0 0 LORI TAUBER-MARCUS VICE CHAIRMAN 2.00 X X 0 0 0 KENNETH ANDERSON MD DIRECTOR 2.00 X 0 0 0 KAREN ANDREWS DIRECTOR 2.00 X 0 0 0 THOMAS CONHEENEY DIRECTOR 2.00 X 0 0 0 RODNEY GILMORE DIRECTOR 2.00 X 0 0 0 W DANA LAFORGE DIRECTOR, THRU DEC. 2021 2.00 X 0 0 0 DAVID LUCCHINO DIRECTOR 2.00 X 0 0 0 HUGH MARTIN DIRECTOR 2.00 X 0 0 0 SUSAN MARVIN DIRECTOR 2.00 X 0 0 0 GERALD MCDOUGALL DIRECTOR 2.00 X 0 0 0 WILLIAM MCKIERNAN DIRECTOR 2.00 X 0 0 0 DAVID PARKINSON MD DIRECTOR 2.00 X 0 0 0 MARIE PINIZZOTTO MD DIRECTOR 2.00 X 0 0 0 RODGER RINEY DIRECTOR, THRU DEC. 2021 2.00 X 0 0 0 ADRIAN ROSENKRANZ DIRECTOR 2.00 X 0 0 0 STEVEN SHAK DIRECTOR 2.00 X 0 0 0 KIMBERLY WHITE DIRECTOR 2.00 X 0 0 0 MICHAEL REINERT DIRECTOR, THRU APRIL 2021 2.00 X 0 0 0 MICHAEL ANDREINI PRESIDENT & CEO 45.00 X 357361 0 19860 ROBERT MIANI TREASURER/CFO 45.00 X 269805 0 20611 KAREN DIETZ SECRETARY/IN-HOUSE COUNSEL 45.00 X 217152 0 18778 ANNE QUINN YOUNG CHIEF MARKETING & DEV. OFFICER 45.00 X 265892 0 18743 DANIEL AUCLAIR CHIEF SCIENTIFIC OFFICER, THRU DEC. 2021 45.00 X 226883 0 10551 STEVEN LABKOFF MD CHIEF DATA OFFICER, THRU JULY 2021 45.00 X 211331 0 26029 PETER KOSA MIF MANAGING DIRECTOR 45.00 X 319603 0 33117 CHANTELLE BRINKLEY DIR, OFFICE OF THE FOUNDER, THRU DEC. 2021 45.00 X 215142 0 8356 MINDY FLINN VP OF DEVELOPMENT 45.00 X 202654 0 17841 CHRISTOPHER WILLIAMS VP OF BUSINESS DEVELOPMENT 45.00 X 199441 0 28082 GREG RUBENSTEIN VP OF MARKETING 45.00 X 183897 0 28791 CATHERINE WACHIRA CLINCAL RESEACH 45.00 X 179100 0 8249 PAUL GIUSTI FORMER PRESIDENT & CEO 0.00 X 352894 0 76 3813610 0 251854 36 1 1 0 REDMEDED LLC 5 GREAT VALLEY PARKWAY SUITE 221 MALVERN PA 19355 CONTINUING MEDICAL EDUCATION 2168520 TGEN 445 N FIFTH STREET PHOENIX AZ 85004 CONTRACT RESEARCH 964532 PRECISION ONCOLOGY PO BOX 75742 BALTIMORE MD 212755742 CONTRACT RESEARCH 959762 CLINICAL RESEARCH SEQUENCING PLATFORM L 415 MAIN STREET CAMBRIDGE MA 02142 CONTRACT RESEARCH 858345 10X GENOMICS INC 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 CONTRACT RESEARCH 717968 35 1461930 35627938 789542 37089868 RESEARCH & CLINICAL TRIALS 541610 2348850 2348850 2348850 100955 100955 98150984 95379461 2771523 2771523 2771523 42311196 2348850 0 2872478 X 6584658 6584658 45000 45000 2640941 1861751 267398 511792 352970 248828 35739 68403 7064425 4980119 715280 1369026 203726 143619 20627 39480 279318 196908 28281 54129 589490 415566 59686 114238 1249249 1104190 24656 120403 222554 196712 7824 18018 57967 51236 2038 4693 5635226 4933071 27226 674929 901453 369408 19201 512844 1247028 1113122 10474 123432 1106913 978382 38914 89617 219313 193847 7710 17756 226614 200300 7967 18347 563341 521059 42282 999369 955139 15359 28871 157549 139255 5539 12755 CLINICAL TRIALS 6822065 6822065 TISSUE BANKING 477894 477894 37647063 32532129 1293919 3821015 X 193984 95390 0 98594 4411175 13953290 50308350 21392706 6260471 5289425 6912455 7335350 403337 225493 4633286 2816485 2293328 1816801 0 29648577 2595830 5648228 91977 91977 73276923 85401847 8304569 12252194 2551261 3265756 8549840 12157093 604023 492004 20009693 28167047 X 39494536 45234580 13772694 12000220 53267230 57234800 73276923 85401847 X 4664133 -49703 -646860 X X 0 1 X 1 0 X 44140691 41335585 39651088 25012712 37089868 187229944 44140691 41335585 39651088 25012712 37089868 187229944 31187405 156042539 373452 1090003 1349522 426629 100955 3340561 190570505 19313913 0.81880 0.76830 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 635825 228556 407269 372411 145303 227108 3625050 2442626 1182424 1816801 CULLINAN MICA 615386 F ABCURO 999997 F INDAPTA 1082849 F FORTIS 500000 F CYTOIMMUNE 1999995 F TRIUMVIRA 450001 F 5648228 DEFERRED RENT EXPENSE PAYABLE 492004 492004 X 41540179 -49703 726437 676734 40863445 1447751 1447751 42311196 37532331 726437 726437 36805894 841169 841169 37647063 PART X, LINE 2: THE MMRF RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE MMRF HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. PART XI, LINE 4B - OTHER ADJUSTMENTS: WRITE-OFF UNCOLLECTIBLE PLEDGES REPORTED ON PART XI, LINE 9 606,582. SPECIAL EVENT EXPENSES RECLASSED TO PART IX 841,169. PART XII, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES RECLASSED TO PART IX 841,169. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTMAKING 45000 0 0 0 0 0 0 45000 0 45000 EUROPE (INCLUDING ICELAND & GREENLAND) FELLOW 37500 WIRE 0 EUROPE (INCLUDING ICELAND & GREENLAND) FELLOW 7500 WIRE 0 2 0 0 0 0 0 0 0 PART I, LINE 2: MMRF RECEIVES PROGRESS REPORTS ON HOW THE GRANTED FUNDS ARE USED. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. PART III ACCOUNTING METHOD: 1 BARBARA ANN KARMANOS CANCER HOSPITAL 4100 JOHN R STREET DETROIT MI 48201 201649466 501(C)(3) 72500 0 SITE INVESTMENT GRANT BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 974200 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 67500 0 FELLOW CITY OF HOPE 1500 EAST DUARTE ROAD MEDICAL OFFICE BLD 3RD FLOOR DURATE CA 91010 953435919 501(C)(3) 370000 0 SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY DANA FARBER CANCER INSTITUTE 44 BINEY ST BOSTON MA 02115 042263040 501(C)(3) 2528537 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION EMORY UNIVERSITY 1365 CLIFTON RD BLDG C ATLANTA GA 30322 580566256 501(C)(3) 737075 0 SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501(C)(3) 37500 0 FELLOW HACKENSACK UNIVERSITY MEDICAL CENTER 360 ESSEX CENTER SUITE 302 HACKENSACK NJ 07601 221487576 501(C)(3) 40000 0 SITE INVESTMENT GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE PO BOX 1075 NEW YORK NY 10029 136171197 501(C)(3) 107000 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY JOHNS HOPKINS MEDICAL INSTITUTIONS 3910 KESWICK ROAD NO N4327B BALTIMORE MD 21211 520595110 501(C)(3) 750000 0 IMMUNOTHERAPY LEVINE CANCER CENTER 1021 MOREHEAD MEDICAL DRIVE CHARLOTTE NC 28204 560529945 501(C)(3) 32500 0 SITE INVESTMENT GRANT MAYO CLINIC - ROCHESTER 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 7500 0 SITE INVESTMENT GRANT MAYO CLINIC - SCOTTSDALE 13400 EAST SHEA BOULEVARD SCOTTSDALE AZ 85259 860800150 501(C)(3) 7500 0 SITE INVESTMENT GRANT MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 315644 0 SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION OHIO STATE UNIVERSITY RESEARCH FOUNDATION B321 STARLING LOVING HALL 320 WEST 10TH AVENUE COLUMBUS OH 43210 316401599 501(C)(3) 32500 0 SITE INVESTMENT GRANT SARAH CANNON RESEARCH INSTITUTE LLC 3322 WEST END ROAD SUITE 900 NASHVILLE TN 37203 201557751 7500 0 SITE INVESTMENT GRANT THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 50000 0 SITE INVESTMENT GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVENUE MC 2115 CHICAGO IL 60637 362177139 STATE OF ILLINOIS 140000 0 SITE INVESTMENT GRANT, FELLOW UCSF MYELOMA RESEARCH PROGRAM 1855 FOLSOM STREET ROOM 423 SAN FRANCISCO CA 94103 946036493 501(C)(3) 22500 0 SITE INVESTMENT GRANT UNIVERSITY OF MICHIGAN 4310 CANCER CENTER 1500 EAST MEDICAL CENTER DRIVE ANN ARBOR MI 48109 386006309 STATE OF MICHIGAN 7500 0 SITE INVESTMENT GRANT UNIVERSITY OF TEXAS- SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BOULEVARD DALLAS TX 75390 756002868 STATE OF TEXAS 72500 0 SITE INVESTMENT GRANT UNIVERSITY OF WISCONSIN 21 N PARK STREET SUITE 6401 MADISON WI 53715 396006492 STATE OF WISCONSIN 7500 0 FELLOW VIRGINIA CANCER SPECIALISTS PC 8503 ARLINGTON BLVD SUITE 320 FAIRFAX VA 22031 541795091 7500 0 SITE INVESTMENT GRANT WASHINGTON UNIVERSITY IN ST LOUIS 660 E EUCLID AVENUE ST LOUIS MO 63110 430653611 501(C)(3) 187827 0 SITE INVESTMENT GRANT, IMMUNOTHERAPY 21 3 PART I, LINE 2: THE OVERALL RESEARCH BUDGET IS PRESENTED TO THE MMRF BOARD. THE BUDGET IS BROKEN DOWN INTO THREE MAIN CATEGORIES WHICH INCLUDE THE FOLLOWING GRANT TYPES: A) DATA BANK: MMRF-SPONSORED LONGITUDINAL MOLECULAR AND IMMUNE STUDIES (COMMPASS AND THE MMRF CURECLOUD). B) LEARNING NETWORK: GATEWAYS, DATA ANALYSIS INITIATIVES, TRANSLATIONAL SITE INVESTMENTS GRANTS (MMRF TRANSLATIONAL NETWORK), TRANSLATIONAL AND IMMUNE PROGRAM GRANTS, RESEARCH FELLOW GRANTS. C) CLINIC: CLINICAL- SITE INVESTMENT GRANTS, CLINICAL FUNDING AGREEMENT GRANTS, PRECISION MEDICINE GRANTS. THE BUDGET SPEND IS INITIALLY APPROVED BY THE PROGRAMMING COMMITTEE, AND THEN THE BOARD GIVES FINAL APPROVAL. 2. DURING THE YEAR, THERE ARE MONTHLY RESEARCH SPEND MEETINGS WITH THE CEO AND CFO TO DISCUSS PROGRESS ON MAKING THE AWARDS. ADDITIONALLY, ANY CHANGES OR REFORECASTS ARE REVIEWED. IF A CHANGE ARISES THAT IS GREATER THAN $1M, THEN IT IS PRESENTED TO THE PROGRAMMING COMMITTEE TO DISCUSS. 3. THERE ARE TWO DISTINCT TYPES OF GRANTS BEING AWARDED: CLASSICAL RESEARCH SUPPORT GRANTS AND CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS. THE ACTUAL AWARDS ARE MADE ACCORDING TO THE BELOW SCHEDULE: A. RESEARCH FELLOW AWARDS- QTR. 3 OR QTR. 4 B. CLINICAL AND TRANSLATIONAL SITE SUPPORT GRANTS QTR. 4 C. OTHER GRANTS ARE MADE THROUGHOUT THE YEAR CLASSICAL RESEARCH GRANTS: GRANTS ARE REVIEWED BY AN EXTERNAL GROUP OF SCIENTISTS WITH THE APPROPRIATE AREAS OF EXPERTISE. SCIENTIFIC RATINGS USE THE CURRENT NIH SCORING SYSTEM OF 1-9 WITH 1 DEMONSTRATING THE HIGHEST SCIENTIFIC MERIT AND 9 BEING THE LOWEST. EACH PROPOSAL IS EVALUATED BY TWO INDEPENDENT OUTSIDE REVIEWERS AND THE SCORES ARE AVERAGED TOGETHER. MOST GRANTS CHOSEN SCORE AT LEAST A 3 OR BETTER. ONCE THE GRANTS ARE RATED EXTERNALLY, FINAL REVIEW IS DONE BY THE MMRF RESEARCH LEADERSHIP AND RECOMMENDATIONS ARE MADE TO THE CEO AND CFO TO CONFIRM THE FINAL SELECTION. AFTER EACH GRANT TYPE AWARD IS MADE, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. AFTER THE FIRST PAYMENT THE RESEARCHER SENDS IN THE REQUIRED PROGRESS REPORT TO RECEIVE REMAINING PAYMENTS. MMRF CONDUCTS A REVIEW PROCESS, DURING WHICH THE INVESTIGATOR'S PROGRESS REPORT IS REVIEWED BY OUTSIDE REVIEWERS TO ENSURE THAT THE APPROPRIATE PROGRESS WAS MADE ON THE STUDY. ONCE THE RESEARCH EMPLOYEE ASSIGNED TO GRANT COORDINATION RECEIVES NOTIFICATION FROM THE REVIEWERS THAT APPROPRIATE PROGRESS WAS MADE AND THE FINDINGS SUPPORT CONTINUES STUDY, HE/SHE PRESENTS THE PROGRESS AND FINDINGS TO AN APPROVAL COMMITTEE FOR A FUNDING RELEASE. CLINICAL/TRANSLATIONAL SITE SUPPORT GRANTS: GRANT PROPOSALS TO SUPPORT MMRF/C CLINICAL OR TRANSLATIONAL SITES ARE REVIEWED BY MMRF RESEARCH STAFF AND LEADERSHIP IN COLLABORATION WITH OUTSIDE ADVISORS. THE MMRF RESEARCH LEADERSHIP THEN MAKES RECOMMENDATIONS TO THE CEO FOR FINAL APPROVAL. AFTER EACH GRANT TYPE AWARD IS APPROVED, AN AWARD LETTER IS SENT TO THE RECIPIENT AND AN EMAIL IS SENT TO THE CFO NOTIFYING THEM OF THE GRANTS AWARDED AND TO PROCEED WITH MAKING THE ACCRUAL FOR THE GRANT. SUCH GRANTS ARE TYPICALLY RENEWED ANNUALLY OR ARE MULTI-YEAR IN NATURE. CONTINUATION/RENEWAL IS AWARDED BASED ON MILESTONES ESTABLISHED UPON INITIATION OF THE PROGRAM. A CONFLICT OF INTEREST POLICY IS IN PLACE AND A COMMITTEE REVIEWS ANY ISSUES THAT MIGHT ARISE WITH ANY GRANTS. X X X X 1 0 0 0 0 0 0 1 0 KATHY GIUSTI FOUNDER & CHIEF MISSION OFFICER 400000 0 60000 0 152455 0 11600 0 1170 0 625225 0 0 0 MICHAEL ANDREINI PRESIDENT & CEO 308054 0 40000 0 9307 0 11600 0 8260 0 377221 0 0 0 PAUL GIUSTI FORMER PRESIDENT & CEO 0 0 0 0 352894 0 0 0 76 0 352970 0 0 0 PETER KOSA MIF MANAGING DIRECTOR 274574 0 23000 0 22029 0 11600 0 21517 0 352720 0 0 0 ROBERT MIANI TREASURER/CFO 243408 0 19000 0 7397 0 10884 0 9727 0 290416 0 0 0 ANNE QUINN YOUNG CHIEF MARKETING & DEV. OFFICER 242689 0 6000 0 17203 0 10855 0 7888 0 284635 0 0 0 DANIEL AUCLAIR CHIEF SCIENTIFIC OFFICER, THRU DEC. 200503 0 6000 0 20380 0 9075 0 1476 0 237434 0 0 0 STEVEN LABKOFF MD CHIEF DATA OFFICER, THRU JULY 2021 160680 0 33000 0 17651 0 8751 0 17278 0 237360 0 0 0 KAREN DIETZ SECRETARY/IN-HOUSE COUNSEL 195026 0 5000 0 17126 0 9008 0 9770 0 235930 0 0 0 CHRISTOPHER WILLIAMS VP OF BUSINESS DEVELOPMENT 184187 0 5000 0 10254 0 8361 0 19721 0 227523 0 0 0 CHANTELLE BRINKLEY DIR, OFFICE OF THE FOUNDER, THRU DEC 175898 0 0 0 39244 0 7375 0 981 0 223498 0 0 0 MINDY FLINN VP OF DEVELOPMENT 196476 0 2000 0 4178 0 8174 0 9667 0 220495 0 0 0 GREG RUBENSTEIN VP OF MARKETING 172885 0 5000 0 6012 0 7757 0 21034 0 212688 0 0 0 CATHERINE WACHIRA CLINCAL RESEACH 171472 0 0 0 7628 0 0 0 8249 0 187349 0 0 0 PART I, LINE 4A THE FOLLOWING EMPLOYEES RECEIVED A SEVERANCE PAYMENT INCLUDED IN THEIR 2021 W-2: PAUL GIUSTI, FORMER PRESIDENT & CEO $352,000 KATHY GIUSTI, FOUNDER & CMO $150,000 CHANTELLE BRINKLEY, HR $30,769 PART I, LINE 7 THE FOLLOWING EMPLOYEES RECEIVED A BONUS FROM THE ORGANIZATION. EACH BONUS WAS BASED ON THE DISCRETION OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS. EACH BONUS WAS BASED UPON A REVIEW OF THE INDIVIDUAL'S PERFORMANCE, AND APPROVED BY THE COMPENSATION COMMITTEE PRIOR TO BEING AWARDED. KATHY GIUSTI, FOUNDER & CMO $60,000 MICHAEL ANDREINI, PRESIDENT & CEO $40,000 ROBERT MIANI, TREASURER/CFO $19,000 KAREN DIETZ, SECRETARY & IN-HOUSE COUNSEL $5,000 STEVEN LABKOFF, MD, CHIEF DATA OFFICER $33,000 ANNE QUINN YOUNG, CHIEF MARKETING & DEVELOPMENT OFFICER $6,000 PETER KOSA, MIF MANAGING DIRECTOR $23,000 DANIEL AUCLAIR, CHIEF SCIENTIFIC OFFICER $6,000 CHRISTOPHER WILLIAMS, VP OF BUSINESS DEVELOPMENT $5,000 MINDY FLINN, VP OF DEVELOPMENT $2,000 GREG RUBENSTEIN, VP OF MARKETING $5,000 X 46 789542 AVG. SELLING PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS. FORM 990, PART I, LINE 1: MMRF ACCOMPLISHMENTS FOR 2021: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AND ITS WHOLLY OWNED SUBSIDIARIES, THE MULTIPLE MYELOMA RESEARCH CONSORTIUM, LLC ("MMRC") AND MYELOMA INVESTMENT FUND, LLC ("MIF"), COLLECTIVELY REFERRED TO AS "THE MMRF," HAS A MISSION TO ACCELERATE A CURE FOR EACH AND EVERY PATIENT WITH MULTIPLE MYELOMA THE SECOND MOST COMMON BLOOD CANCER. THE MMRF, WITH ITS END-TO END PRECISION MEDICINE MODEL, COLLABORATES WITH ITS PARTNERS TO ADVANCE BASIC AND TRANSLATIONAL RESEARCH, AND MOVE THE BEST IDEAS RAPIDLY INTO CLINICAL TRIALS. THE MMRF ALSO ENGAGES WITH PATIENTS AND THEIR FRIENDS AND FAMILIES TO EDUCATE AND EMPOWER THEM TO OPTIMIZE THEIR OUTCOMES. THE MMRF WAS INCORPORATED ON JANUARY 13, 1998. THE PROVEN NETWORK OF THE MMRF ENGAGES THE BEST NEW SCIENCE AND TECHNOLOGY TO ACCELERATE DEVELOPMENT OF TREATMENTS FOR PATIENTS AS QUICKLY AS POSSIBLE. IT IS BASED ON THREE PILLARS: ACCELERATING THE DEVELOPMENT OF NEW TREATMENTS, DRIVING PRECISION MEDICINE, AND EMPOWERING PATIENTS AND THE ENTIRE COMMUNITY. IN 2021, WE CONTINUED TO ADVANCE THE KEY INITIATIVES OF OUR STRATEGIC PLAN WHICH IS ANCHORED BY THREE STRATEGIC OBJECTIVES, WITH A CENTRALIZED FOCUS ON DEI AND HEALTH EQUITY. - ACCELERATE THE DEVELOPMENT OF NOVEL THERAPIES - DRIVE OPTIMAL AND MORE PERSONALIZED TREATMENT APPROACHES - EMPOWER PATIENTS AND THE MYELOMA COMMUNITY PATIENT SERVICES AND EDUCATION ADVANCING PATIENT HEALTH AND WELL-BEING THROUGH EDUCATION - PATIENT EDUCATION WEBINARS AND SUMMITS REACHED 10,000 PATIENTS AND CAREGIVERS IN 2021. - IN 2021, THE MMRF PATIENT NAVIGATION CENTER ANSWERED 4,800 CALLS, ADDRESSED MORE THAN 3,350 CASES, AND OVER 200 REFERRALS TO MYELOMA SPECIALISTS. ITS EXEMPLARY SERVICE HAS EARNED A 5-STAR SATISFACTION RATING FROM THE MYELOMA COMMUNITY. FORM 990, PART III, LINE 1: A PIONEER IN PRECISION MEDICINE, THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SEEKS TO ACCELERATE A CURE FOR EACH AND EVERY MULTIPLE MYELOMA PATIENT. FOUNDED IN 1998 BY KATHY GIUSTI, A MULTIPLE MYELOMA PATIENT, AND HER TWIN SISTER KAREN ANDREWS AS A 501(C)(3) NONPROFIT ORGANIZATION, THE MMRF IDENTIFIES BARRIERS AND THEN FINDS THE SOLUTIONS TO OVERCOME THEM, BRINGING IN THE BEST PARTNERS AND ACTING AS A CATALYST OR SYNERGIST TO DRIVE BETTER OUTCOMES FOR PATIENTS. SINCE ITS INCEPTION, THE ORGANIZATION HAS COLLECTED THOUSANDS OF TISSUE SAMPLES, OPENED NEARLY 100 TRIALS, HELPED BRING 15 FDA-APPROVED THERAPIES TO MARKET, AND BUILT COMMPASS, THE SINGLE LARGEST GENOMIC DATASET FOR ANY CANCER. TODAY, THE MMRF IS BUILDING ON ITS LEGACY IN GENOMICS AND IS EXPANDING INTO IMMUNOTHERAPY, AS THE COMBINATION OF THESE TWO FIELDS WILL BE CRITICAL TO MAKING PRECISION MEDICINE POSSIBLE FOR ALL PATIENTS. THE MMRF HAS RAISED MORE THAN $500 MILLION AND DIRECTS NEARLY 90% OF THE TOTAL FUNDS TO RESEARCH AND RELATED PROGRAMS. FORM 990, PART VI, SECTION A, LINE 2 KATHY GIUSTI, FOUNDER & CHIEF MISSION OFFICER, AND KAREN ANDREWS, BOARD MEMBER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED WITH THE CEO OF THE FOUNDATION. ONCE REVIEWED WITH THE CEO, THE FORM 990 IS EMAILED TO EACH BOARD MEMBER. EACH BOARD MEMBER REVIEWS THE FORM 990 AND IF ANY QUESTIONS ARISE, THEY ARE COMMUNICATED TO THE FOUNDATION AND ADDRESSED. AFTER ALL QUESTIONS ARE ADDRESSED, THE FORM 990 IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO ANY DIRECTOR, OFFICER, OR MEMBER OF A STANDING OR ADVISORY COMMITTEE WITH POWERS DELEGATED BY THE MMRF BOARD OF DIRECTORS WHO MAY HAVE A DIRECT OR INDIRECT FINANCIAL INTEREST (I.E. "INTERESTED PERSON"). DUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST: ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR AUDIT COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE AUDIT COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR AUDIT COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR AUDIT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR AUDIT COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE AUDIT COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE AUDIT COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRF'S BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRF'S CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY: III. IF THE BOARD OR AUDIT COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR AUDIT COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR AUDIT COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15 ALL SENIOR POSITIONS AND THEIR COMPENSATION ARE REVIEWED AND APPROVED BY THE HR COMMITTEE OF THE BOARD OF DIRECTORS. COMPENSATION IS BENCHMARKED AGAINST OTHER 501(C)(3)'S, RESEARCH ORGANIZATIONS, THIRD PARTY COMPENSATION DATABASE AND THEN REVIEWED BY THE COMPENSATION COMMITTEE. THE COMPENSATION APPROVAL IS DOCUMENTED IN THE MINUTES BY THE COMMITTEE. THIS PROCESS WAS LAST UNDERTAKEN IN 2021. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, FORM 990 AND FORM 1023 ARE MADE AVAILABLE FOR PUBLIC VIEWING UPON WRITTEN REQUEST AT MMRF'S HEADQUARTERS LOCATED AT 383 MAIN AVENUE, 5TH FLOOR, NORWALK, CT 06851. FORM 990 AND AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE AT THE ORGANIZATION'S WEBSITE: WWW.THEMMRF.ORG THE FORM 990 IS ALSO AVAILABLE ON WWW.GUIDESTAR.ORG, WWW.CHARITYNAVIGATOR.ORG, AND OTHER SIMILAR WEBSITES. FORM 990, PART IX, LINE 11G CONSULTING: PROGRAM SERVICE EXPENSES 2,019,449. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 265,296. TOTAL EXPENSES 2,284,745. MEDICAL PROFESSIONALS: PROGRAM SERVICE EXPENSES 2,720,982. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 357,457. TOTAL EXPENSES 3,078,439. RECRUITING COSTS & TEMPORARY HELP: PROGRAM SERVICE EXPENSES 192,640. MANAGEMENT AND GENERAL EXPENSES 27,226. FUNDRAISING EXPENSES 52,176. TOTAL EXPENSES 272,042. FORM 990, PART XI, LINE 9: WRITE-OFF OF UNCOLLECTIBLE PLEDGES -606,582. LOSS ON DISPOSAL OF ASSETS -40,278. FORM 990, PART XII, LINE 2C: THE MULTIPLE MYELOMA RESEARCH FOUNDATION, INC. AUDIT/FINANCE COMMITTEE RECOMMENDS THE AUDITOR TO THE BOARD, AND THE BOARD APPOINTS THE AUDITOR. THE BOARD ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS. THE POLICY FOR SELECTION AND OVERSIGHT OF THE INDEPENDENT AUDITORS HAS NOT CHANGED SINCE LAST YEAR. MYELOMA INVESTMENT FUND LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471162865 VENTURE PHILANTHROPY FUND DE 4463381 17364904 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC MULTIPLE MYELOMA RESEARCH CONSORTIUM LLC 383 MAIN AVENUE 5TH FLOOR NORWALK CT 06851 471142650 FACILITATING OR SPONSORING CLINICAL TRIALS AND RELATED RESEARCH CT 3744875 2893293 THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC